Quest PharmaTech Inc.
QPT.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -47.52% | 47.67% | -56.08% | -64.10% | 4,160.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.32% | 55.85% | -71.26% | -41.85% | 62.07% |
| Operating Income | 25.32% | -55.85% | 71.26% | 41.85% | -62.07% |
| Income Before Tax | 18.67% | 104.54% | 507.05% | -704.56% | 96.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.67% | 104.54% | 507.05% | -704.56% | 96.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.67% | 104.54% | 507.05% | -704.56% | 96.83% |
| EBIT | 25.32% | -55.85% | 71.26% | 41.85% | -62.07% |
| EBITDA | 25.51% | -55.33% | 71.25% | 42.14% | -62.38% |
| EPS Basic | 19.54% | 106.06% | 487.50% | -660.00% | 96.85% |
| Normalized Basic EPS | 11.11% | 66.67% | 280.00% | -633.33% | -5.88% |
| EPS Diluted | 19.54% | 106.06% | 487.50% | -660.00% | 96.85% |
| Normalized Diluted EPS | 11.11% | 66.67% | 280.00% | -633.33% | -5.88% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 1.08% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 1.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |